We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+83.78%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$212M
Cap. Flow
-$46.3M
Cap. Flow %
-4.15%
Top 10 Hldgs %
42.31%
Holding
75
New
24
Increased
13
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$25.4M
2
VSTM icon
Verastem
VSTM
+$22.7M
3
PCVX icon
Vaxcyte
PCVX
+$20.7M
4
LBRX
LB Pharmaceuticals
LBRX
+$17.9M
5
ARVN icon
Arvinas
ARVN
+$17.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$30M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$26.5M
3
UTHR icon
United Therapeutics
UTHR
+$24.4M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
5
KROS icon
Keros Therapeutics
KROS
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 90.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
51
PepGen
PEPG
$127M
$3.46M 0.31%
+750,000
New +$1.21M
ACRS icon
52
Aclaris Therapeutics
ACRS
$744M
$2.85M 0.26%
1,500,000
-350,000
-19% -$610K
UNCY icon
53
Unicycive Therapeutics
UNCY
$135M
$2.06M 0.19%
473,563
+1
+0% +$4
ESPR
54
DELISTED
Esperion Therapeutics
ESPR
$1.99M 0.18%
+750,000
New +$1.45M
SEPN
55
Septerna Inc
SEPN
$1.53B
$1.57M 0.14%
83,548
-25,654
-23% -$337K
ALEC icon
56
CALL
Alector
ALEC
$169M
$1.48M 0.13%
+500,000
New +$1.1M
MREO
57
Mereo BioPharma
MREO
$48.2M
$1.03M 0.09%
+500,000
New +$922K
GUTS icon
58
Fractyl Health
GUTS
$115M
$795K 0.07%
+500,000
New +$649K
NUVB.WS
59
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.5K ﹤0.01%
66,666
– –
ANNX icon
60
Annexon
ANNX
$814M
– –
-2,410,000
Closed -$5.78M
ARVN icon
61
CALL
Arvinas
ARVN
$529M
– –
-1,500,000
Closed -$11M
BHVN icon
62
Biohaven
BHVN
$2.07B
– –
-700,000
Closed -$9.88M
CLDX icon
63
Celldex Therapeutics
CLDX
$2.79B
– –
-600,000
Closed -$12.2M
KRYS icon
64
Krystal Biotech
KRYS
$10.7B
– –
-100,000
Closed -$13.7M
LEGN icon
65
Legend Biotech
LEGN
$3.68B
– –
-250,000
Closed -$8.87M
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-50,000
Closed -$15.1M
MLTX icon
67
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-200,000
Closed -$9.44M
NBIX icon
68
Neurocrine Biosciences
NBIX
$18.4B
– –
-150,000
Closed -$18.9M
TEVA icon
69
CALL
Teva Pharmaceuticals
TEVA
$36.9B
– –
-1,500,000
Closed -$25.1M
UTHR icon
70
United Therapeutics
UTHR
$26.1B
– –
-85,000
Closed -$24.4M
XBI icon
71
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-1,000,000
Closed -$82.9M
XNCR icon
72
Xencor
XNCR
$1.48B
– –
-1,250,000
Closed -$9.82M
RAPP
73
Rapport Therapeutics
RAPP
$2.01B
– –
-208,910
Closed -$2.38M
BCAX
74
Bicara Therapeutics
BCAX
$1.77B
– –
-400,000
Closed -$3.72M
MTSR
75
DELISTED
Metsera Inc
MTSR
– –
-200,000
Closed -$5.69M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2025 Portfolio in Review

As of Q3 2025, Logos Global Management held 75 positions worth $1.12B, up 23% from $904M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Logos Global Management withdrew a net $46.3M in Q3 2025, closing 16 positions and reducing 13 holdings. Its most notable exit was United Therapeutics, an estimated $24.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 83% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Abivax worth $35.2M.

  • Logos Global Management's largest Q3 2025 buy was Abivax: 415,000 shares worth $35.2M.
  • Logos Global Management added most to Verastem in Q3 2025, an estimated $22.7M increase.
  • Logos Global Management's biggest Q3 2025 reduction was Jazz Pharmaceuticals, cutting an estimated $30M.
  • Logos Global Management fully exited United Therapeutics in Q3 2025, selling an estimated $24.4M.
  • Logos Global Management's ten largest holdings make up 42% of its $1.12B portfolio in Q3 2025.
  • Logos Global Management opened 24 new positions and closed 16 in Q3 2025.
  • Logos Global Management's portfolio value rose 23% quarter-over-quarter to $1.12B.

Based on Logos Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.